logo-loader
viewFaron Pharmaceuticals Ltd

Faron Pharmaceuticals makes 'groundbreaking discovery' in its MATINS trial

Faron Pharmaceuticals Oy (LON:FARN) (FIRSTNORTH:FARON) CEO Dr Markku Jalkanen speaks to Proactive London's Andrew Scott after updating on its phase I/II MATINS trial of Clevegen.

He says it's been encouraging to discover that Clevegen can ‘down’ regulate a range of checkpoints that affect the immune system.

Quick facts: Faron Pharmaceuticals Ltd

Price: 237.5 GBX

AIM:FARN
Market: AIM
Market Cap: £102.82 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: Faron Pharma expands MATINS trial to include ovarian cancer

Headlines from the Proactive UK newsroom. Faron Pharmaceuticals (LON:FARN) is to expand its phase I/II MATINS clinical trial of its Clevegen cancer drug to women with ovarian cancer. Earlier this month, Faron was also given permission to expand the ongoing trial into late-stage colorectal...

1 day, 20 hours ago

2 min read